Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease

Journal of Experimental Medicine

Volumn 203, Issue 13, 2006, Pages 2785-2791

  Lohr, Jens ^a   Knoechel, Birgit ^a   Jing, Jing Wang ^a   Villarino, Alejandro V ^a   Abbas, Abul K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL;

ADOPTIVE TRANSFER; ALOPECIA; ANIMALS; AUTOIMMUNE DISEASES; BODY WEIGHT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FEMALE; GRAFT VS HOST DISEASE; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-17; INTERLEUKIN-2; INTERLEUKIN-4; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; OVALBUMIN; SKIN; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 33845910939     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20061341     Document Type: Article

References (29)

1. Feldmann, M., and L. Steinman. 2005. Design of effective immunotherapy for human autoimmunity. Nature. 435:612-619.
2. Feldmann, M., F.M. Brennan, B.M. Foxwell, P.C. Taylor, R.O. Williams, and R.N. Maini. 2005. Anti-TNF therapy: where have we got to in 2005? J. Autoimmun. 25(Suppl):26-28.
3. Moseley, T.A., D.R. Haudenschild, L. Rose, and A.H. Reddi. 2003. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 14:155-174.
4. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171:6173-6177.
5. Nakae, S., S. Saijo, R. Horai, K. Sudo, S. Mori, and Y. Iwakura. 2003. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl. Acad. Sci. USA. 100:5986-5990.
6. Witowski, J., K. Ksiazek, and A. Jorres. 2004. Interleukin-17: a mediator of inflammatory responses. Cell. Mol. Life Sci. 61:567-579.
7. Ogawa, A., A. Andoh, Y. Araki, T. Bamba, and Y. Fujiyama. 2004. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin. Immunol. 110:55-62.
8. Kolls, J.K., and A. Linden. 2004. Interleukin-17 family members and inflammation. Immunity. 21:467-476.
9. McKenzie, B.S., R.A. Kastelein, and D.J. Cua. 2006. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 27:17-23.
10. You, S., G. Slehoffer, S. Barriot, J.F. Bach, and L. Chatenoud. 2004. Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc. Natl. Acad. Sci. USA. 101(Suppl 2):14580-14585.
11. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531-562.
12. Horwitz, D.A., J.D. Gray, and S.G. Zheng. 2002. The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases. Arthritis Res. 4:241-246.
13. Veldhoen, M., R.J. Hocking, C.J. Atkins, R.M. Locksley, and B. Stockinger. 2006. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 24:179-189.
14. Mangan, P.R., L.E. Harrington, D.B. O'Quinn, W.S. Helms, D.C. Bullard, C.O. Elson, R.D. Hatton, S.M. Wahl, T.R. Schoeb, and C.T. Weaver. 2006. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 441:231-234.
15. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, H.L. Weiner, and V.K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 441:235-238.
16. Knoechel, B., J. Lohr, E. Kahn, J.A. Bluestone, and A.K. Abbas. 2005. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J. Exp. Med. 202:1375-1386.
17. Szabo, S.J., S.T. Kim, G.L. Costa, X. Zhang, C.G. Fathman, and L.H. Glimcher. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 100:655-669.
18. Sawitzki, B., C.I. Kingsley, V. Oliveira, M. Karim, M. Herber, and K.J. Wood. 2005. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J. Exp. Med. 201:1925-1935.
19. Harrington, L.E., R.D. Hatton, P.R. Mangan, H. Turner, T.L. Murphy, K.M. Murphy, and C.T. Weaver. 2005. Interleukin 17- producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:1123-1132.
20. Park, H., Z. Li, X.O. Yang, S.H. Chang, R. Nurieva, Y.H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133-1141.
21. Cousens, L.P., J.S. Orange, and C.A. Biron. 1995. Endogenous IL-2 contributes to T cell expansion and IFN-gamma production during lymphocytic choriomeningitis virus infection. J. Immunol. 155:5690-5699.
22. Nelson, B.H. 2004. IL-2, regulatory T cells, and tolerance. J. Immunol. 172:3983-3988.
23. Walker, L.S., A. Chodos, M. Eggena, H. Dooms, and A.K. Abbas. 2003. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J. Exp. Med. 198:249-258.
24. Reddy, P. 2003. Pathophysiology of acute graft-versus-host disease. Hematol. Oncol. 21:149-161.
25. Murphy, W.J., L.A. Welniak, D.D. Taub, R.H. Wiltrout, P.A. Taylor, D.A. Vallera, M. Kopf, H. Young, D.L. Longo, and B.R. Blazar. 1998. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J. Clin. Invest. 102:1742-1748.
26. Yang, Y.G., B.R. Dey, J.J. Sergio, D.A. Pearson, and M. Sykes. 1998. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J. Clin. Invest. 102:2126-2135.
27. Cua, D.J., and R.A. Kastelein. 2006. TGF-beta, a 'double agent' in the immune pathology war. Nat. Immunol. 7:557-559.
28. Knoechel, B., J. Lohr, S. Zhu, L. Wong, D. Hu, L. Ausubel, and A.K. Abbas. 2006. Functional and molecular comparison of anergic and regulatory T lymphocytes. J. Immunol. 176:6473-6483.
29. Anderson, B.E., J.M. McNiff, D. Jain, B.R. Blazar, W.D. Shlomchik, and M.J. Shlomchik. 2005. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood. 105:2227-2234.